US5028608A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
Assignee: Princeton University
•
Filing: 1990-05-24
•
Granted: 1991-07-02
•
Expires: 2010-05-24
Abstract
Abstract N-(Acyl)glutamic acid derivatives in which the acyl group is substituted with 4-hydroxypyrrolo[2,3-d]-pyrimidin-3-yl group are antineoplastic agents. A typical embodiment is N-{5-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)ethyl]thien-2-ylcarbonyl}-L-glutamic acid.
Inventors
- 👤 Edward C. Taylor
- 👤 Dietmar G. Kuhnt
- 👤 Chuan Shih
- 👤 Gerald B. Grindey
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 02:27
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/04
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
64 words
A compound of the formula: ##STR16## in which: R 1 is --OH or --NH 2 ; R 3 is thienediyl or furanediyl unsubstituted or substituted with chloro, fluoro, methyl, methoxy, or trifluoromethyl; cyclohexadiyl; and alkanediyl having 2 to 4 carbon atoms; R 4 is hydrogen, methyl, orhydroxymethyl; and the configuration about the carbon atom designated * is S; and the pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim
64 words
A compound of the formula: ##STR16## in which: R 1 is --OH or --NH 2 ; R 3 is thienediyl or furanediyl unsubstituted or substituted with chloro, fluoro, methyl, methoxy, or trifluoromethyl; cyclohexadiyl; and alkanediyl having 2 to 4 carbon atoms; R 4 is hydrogen, methyl, orhydroxymethyl; and the configuration about the carbon atom designated * is S; and the pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
20 words
A compound according to claim 1 wherein R 1 is --OH; R 3 is thienediyl, and R 4 is hydrogen.
Claim 4
Dependent Claim
10 words
The compound according to claim 1 which is N-{5-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)-ethyl]thien-2-ylcarbonyl}-L-glutamic acid.
Claim 5
Dependent Claim
10 words
The compound according to claim 1 which is N-{4-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)-ethyl]thien-2-ylcarbonyl}-L-glutamic acid.
Claim 6
Dependent Claim
10 words
The compound according to claim 1 which is N-{5-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)ethyl]thien-3-ylcarbonyl}-L-glutamic acid.
Claim 7
Dependent Claim
10 words
The compound according to claim 1 which is N-[5-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)pentanoyl]-L-glutamic acid.
Claim 8
Dependent Claim
10 words
The compound according to claim 1 which is N-[7-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)heptanoyl]-L-glutamic acid.
Claim 9
Dependent Claim
10 words
The compound according to claim 1 which is N-[6-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)hexanoyl]-L-glutamic acid
Claim 10
Dependent Claim
32 words
The method of combatting neoplastic growth in a mammal which comprises administering to the mammal in a single or multiple dose regimen an effective amount of a compound according to claim 1.
Claim 11
Dependent Claim
47 words
A pharmaceutical composition for combatting neoplastic growth in a mammal which comprises an amount of a compound according to claim 1 which upon administration to the mammal in a single or multiple dose regimen is effective to combat said growth, in combination with a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
105 words
A compound of the formula: ##STR17## in which: R 1 is --OH or --NH 2 ; R 2' is hydrogen, or a carboxy protecting group; R 3 is thienediyl or furanediyl unsubstituted or substituted with chloro, fluoro, methyl, methoxy, or trifluoromethyl, cyclohexadiyl, or alkanediyl having 2 to 4 carbon atoms; R 4' is hydrogen, methyl, hydroxymethyl, or hydroxymethyl substituted with a hydroxy protecting group; and R 5' is amino or amino substituted with an amino protecting group, at least one of R 2' , R 4' , and R 5 being a carboxy protecting group, a hydroxy protecting group, or an amino protecting group, respectively.
Claim 13
Dependent Claim
105 words
A compound of the formula: ##STR17## in which: R 1 is --OH or --NH 2 ; R 2' is hydrogen, or a carboxy protecting group; R 3 is thienediyl or furanediyl unsubstituted or substituted with chloro, fluoro, methyl, methoxy, or trifluoromethyl, cyclohexadiyl, or alkanediyl having 2 to 4 carbon atoms; R 4' is hydrogen, methyl, hydroxymethyl, or hydroxymethyl substituted with a hydroxy protecting group; and R 5' is amino or amino substituted with an amino protecting group, at least one of R 2' , R 4' , and R 5 being a carboxy protecting group, a hydroxy protecting group, or an amino protecting group, respectively.
References Cited (Backward Citations)
US3856959A
Cited
GB1534238A
Cited
US4172200A
Cited
US4369319A
Cited
US4564616A
Cited
US4512992A
Cited
US4431805A
Cited
US4526964A
Cited
US4536575A
Cited
US4460591A
Cited
US4532241A
Cited
US4432981A
Cited
WO1985002844A1
Cited
US4684653A
Cited
US4845216A
Cited
US4927828A
Cited
US4833145A
Cited
US4818819A
Cited
US4902796A
Cited
US4831037A
Cited
US4895946A
Cited
US4871743A
Cited
US4889859A
Cited
EP0334636A2
Cited
US4882333A
Cited
US4882334A
Cited
US4871746A
Cited
US4883799A
Cited
US4920125A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-01 | 1994-12-31 | 1995-07-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-01 | 1998-12-31 | 1999-07-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-01 | 2002-12-31 | 2003-07-02 | $7700.00 | Window Closed / Lapsed |